tetrabenazine-xenazine

Description: Tetrabenazine (Ro 1-9569; trade name: Nitoman and Xenazin), a VMAT-inhibitor, is an FDA approved drug for the treatment of symptomatic treatment of hyperkinetic movement disorder. FDA approved the use of tetrabenazine to treat chorea associated with Huntington's disease (HD) On August 15, 2008, which is the first in the US. The precise mechanism of action of tetrabenazine is unknown. The antichorea effect is believed to be related to its effect as a reversible depletory of monoamines (such as dopamine, serotonin, norepinephrine and histamine)from nerve terminals)

References: Neurology. 1997 Feb; 48(2):358-62; Ann Pharmacother. 2011 Apr; 45(4):525-31.

Related CAS#:718635-93-9 (Tetrabenazine Racemate); 1392826-25-3 (Tetrabenazine D6); 1026016-83-0 Tetrabenazine ((+)-); (+)-Tetrabenazine; (+)-TBZ; (3R, 11bR)-TBZ; (3R, 11bR)-Tetrabenazine); 1977511-05-9 (+)-Tetrabenazine D6